Gilead Sciences (NASDAQ:GILD) traded on a positive note gaining 1.14 points or 1.25% to be valued at $92.46 per share. Intraday, the shares aggregated $143.88 million in upticks but saw an exodus of $152.05 million in downticks. The net money flow was calculated to be $(-8.17) million with the final up/down ratio coming in at 0.95. The share price has seen a change of 1.25% in value during the week. Block trade of up/down ratio of 8.91 was also registered with $9.61 million in upticks and $1.08 million in downticks. The net money flow for the block exchange was disappointing at $(8.53) Million.
The stock has recorded a 20-day Moving Average of 3.51% and the 50-Day Moving Average is 4.33%. Shares of Gilead Sciences Inc. rose by 2.43% in the last five trading days and 3.05% for the last 4 weeks. Gilead Sciences Inc. has dropped 9.92% during the last 3-month period . Year-to-Date the stock performance stands at -8.19%.
Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP, Corp & Med Affairs) of Gilead Sciences Inc, Alton Gregg H had sold 5,000 shares worth of $450,000 in a transaction dated March 14, 2016. In this transaction, 5,000 shares were sold at $90 per share. Currently the company Insiders own 1.61% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.29% . Institutional Investors own 82.24% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -0.1%.
Gilead Sciences (NASDAQ:GILD) rose 1.25% or 1.14 points on Monday and made its way into the gainers of the day. After trading began at $92.07 the stock was seen hitting $94.31 as a peak level and $91.94 as the lowest level. The stock ended up at $92.46. The daily volume was measured at 9,606,762 shares. The 52-week high of the share price is $123.37 and the 52-week low is $81.89. The company has a market cap of $126,379 million.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.